Freder1k-Study - Testing Infants for Type 1 Diabetes Risk

Helmholtz Zentrum München

Status

Enrolling

Conditions

Identification of Infants at Risk for Type 1 Diabetes

Study type

Observational

Funder types

Industry

Identifiers

NCT03316261

GPPAD-02

Details and patient eligibility

About

The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.

Full description

Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type 1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss, thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies. Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies and type 1 diabetes can now be identified using genetic markers. This provides opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.

Enrollment

1,000,000 estimated patients

Sex

All

Ages

1 day to 6 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria